{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T09:35:32.760177+00:00","company":{"ticker":"SBFM","cik":1402328,"company_name":"Sunshine Biopharma Inc."},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"db609ecd9fb89d0f05b3a6b57c3059703e7c6b7c","cik":1402328,"ticker":"SBFM","company_name":"Sunshine Biopharma Inc.","filed_at":"2026-04-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the year ended December 31, 2025","report_date":"2026-04-06","result_type":"reported_results","revenue_text":"$36.3 million"},"claim":"Sunshine Biopharma Inc. reported the year ended December 31, 2025 results: revenue $36.3 million.","evidence_excerpt":"specific reference in such filing. \n\n--- EX-99.1 (PRESS RELEASE) ---\n\nEX-99.1 2 sunshine_ex9901.htm PRESS RELEASE Exhibit 99.1 Sunshine\nBiopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year FORT LAUDERDALE, FL / ACCESSWIRE\n/ April 6, 2026 — Sunshine Biopharma Inc. (NASDAQ: SBFM) (“Sunshine Biopharma” or the “Company”), a","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001683168-26-002781","anchor_url":"https://secwatch.observer/filing/0001683168-26-002781#claim-db609ecd9fb89d0f05b3a6b57c3059703e7c6b7c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826002781/0001683168-26-002781-index.htm"},{"fact_type":"auditor_change","fact_key":"4abb82b6fefb231326695b1f2d8c9eede0583603","cik":1402328,"ticker":"SBFM","company_name":"Sunshine Biopharma Inc.","filed_at":"2025-09-30T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"M&K CPAS, PLLC","disagreement_text":null,"effective_date":"2025-09-24","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Sunshine Biopharma Inc. engaged M&K CPAS, PLLC as its auditor.","evidence_excerpt":"ublic accounting firm and retained M&K CPAS, PLLC (“M&K”) as its independent auditor. The decision to dismiss Bush\n& Associates and retain M&K was approved by the unanimous consent of the Company’s board of directors and the Company’s","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001683168-25-007338","anchor_url":"https://secwatch.observer/filing/0001683168-25-007338#claim-4abb82b6fefb231326695b1f2d8c9eede0583603","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316825007338/0001683168-25-007338-index.htm"},{"fact_type":"auditor_change","fact_key":"ae32be9197b449faf3c40f986c5cabdb54631add","cik":1402328,"ticker":"SBFM","company_name":"Sunshine Biopharma Inc.","filed_at":"2025-09-30T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Bush & Associates CPA LLC","disagreement_text":null,"effective_date":"2025-09-24","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"M&K CPAS, PLLC"},"claim":"Sunshine Biopharma Inc. dismissed Bush & Associates CPA LLC as its auditor.","evidence_excerpt":"Effective September 24, 2025, Sunshine Biopharma Inc. (the “Company”), dismissed Bush & Associates CPA LLC (“Bush & Associates”), as its independent registered public accounting firm and retained M&K CPAS, PLLC (“M&K”) as its independent auditor.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001683168-25-007338","anchor_url":"https://secwatch.observer/filing/0001683168-25-007338#claim-ae32be9197b449faf3c40f986c5cabdb54631add","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316825007338/0001683168-25-007338-index.htm"},{"fact_type":"executive_change","fact_key":"59959e578e","cik":1402328,"ticker":"SBFM","company_name":"Sunshine Biopharma Inc.","filed_at":"2025-01-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-13","interim":false,"role":"Chief Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Michel Roy was appointed as Chief Commercial Officer at Sunshine Biopharma Inc..","evidence_excerpt":"On January 13, 2025, Sunshine Biopharma Inc. (the “Company”) appointed Mr. Michel Roy as the Company’s Chief Commercial Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001683168-25-000357","anchor_url":"https://secwatch.observer/filing/0001683168-25-000357#claim-59959e578e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316825000357/0001683168-25-000357-index.htm"},{"fact_type":"auditor_change","fact_key":"b3d9b693e90d1d484cd08aa8f72a2e1ced26b319","cik":1402328,"ticker":"SBFM","company_name":"Sunshine Biopharma Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Bush & Associates CPA LLC","disagreement_text":null,"effective_date":"2024-05-07","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Sunshine Biopharma Inc. engaged Bush & Associates CPA LLC as its auditor.","evidence_excerpt":"Sunshine Biopharma, Inc. (the “Company”), retained Bush & Associates CPA LLC (“Bush & Associates”), as its independent registered public accounting firm.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001683168-24-003104","anchor_url":"https://secwatch.observer/filing/0001683168-24-003104#claim-b3d9b693e90d1d484cd08aa8f72a2e1ced26b319","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824003104/0001683168-24-003104-index.htm"},{"fact_type":"auditor_change","fact_key":"3f43b1d7c68fe67a0b368ce6e46469d857336007","cik":1402328,"ticker":"SBFM","company_name":"Sunshine Biopharma Inc.","filed_at":"2024-05-06T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"BF Borgers CPA, PC","disagreement_text":null,"effective_date":"2024-05-03","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Sunshine Biopharma Inc. dismissed BF Borgers CPA, PC as its auditor.","evidence_excerpt":"udited by BF Borgers CPA, PC (“Borgers”). On May 3, 2024, the Securities and Exchange Commission (the “SEC”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001683168-24-003004","anchor_url":"https://secwatch.observer/filing/0001683168-24-003004#claim-3f43b1d7c68fe67a0b368ce6e46469d857336007","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824003004/0001683168-24-003004-index.htm"}]}